Bioavailability and Vascular Effects of Apple Polyphenols

NCT ID: NCT01097226

Last Updated: 2013-03-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-04-30

Study Completion Date

2011-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of this study is to determine the oral bioavailability of flavanols (polyphenolic compounds) from apple granules and an apple extract delivered in a water based beverage at two different doses. We will also investigate the effects of apple flavanols on nitric oxide production.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is a randomized four phase crossover trial investigating the bioavailability of apple flavanols and the effects on nitric oxide products, a surrogate marker for changes in endothelial function. Each test phase will comprise a 3 day period of intervention which will be identical in nature (except for the test product consumed) and separated by a minimum of 1 week. On days 1-3 of each test phase volunteers will consume a low flavanol diet. After consumption of the test product on the morning of day 2, blood and urine samples will be collected at regular intervals for the next 24h.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Apple flavanols

Group Type EXPERIMENTAL

Apple extract delivering 70 mg epicatechin

Intervention Type OTHER

Delivered as a flavoured water based beverage

Apple extract delivering 140 mg epicatechin

Intervention Type OTHER

Delivered as a flavoured water based beverage

Apple granules delivering 70 mg epicatechin

Intervention Type OTHER

Delivered as a puree

Water delivering no epicatechin

Intervention Type OTHER

Delivered as flavoured water

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Apple extract delivering 70 mg epicatechin

Delivered as a flavoured water based beverage

Intervention Type OTHER

Apple extract delivering 140 mg epicatechin

Delivered as a flavoured water based beverage

Intervention Type OTHER

Apple granules delivering 70 mg epicatechin

Delivered as a puree

Intervention Type OTHER

Water delivering no epicatechin

Delivered as flavoured water

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men and women aged 45-70 years

Exclusion Criteria

* Smokers (or have quit smoking less than 1 year ago)
* Regular prescribed medication (excluding some eye and skin medication that is judged not to affect study outcome)
* Non-prescribed medication that may affect the study data, e.g. aspirin. The use of non prescribed medications will be assessed on an individual basis.
* Dietary supplements or herbal remedies which may affect the study data unless the volunteer is willing to discontinue them for 1 month prior to starting study. (Please note that some supplements may not affect the study and this will be assessed on an individual basis).
* Gastro-intestinal diseases (excluding hiatus hernia unless symptomatic or study intervention/procedure is contra-indicated).
* Diabetics
* Known cardiovascular disease
* Asthmatics (unless no medication taken for 1 year)
* Lactose Intolerance
* Pregnancy or have been pregnant within the last 12 months
* Parallel participation in another research project which involves dietary intervention
* Participation in another research project which has involved blood sampling within the last four months unless the total amount of combined blood from both studies does not exceed 470 mls.
* Has donated or intends to donate blood within 16 weeks prior to or during the study period.
* Depressed or elevated blood pressure measurements (\<90/50 or 95/55 if symptomatic or \>160/100)
* Any person related to or living with any member of the study team
* Results of the clinical screening which indicate or are judged by the HNU Medical Advisor to be indicative of a health problem which could compromise the well-being of the volunteer if they participated or which could affect the study data.
* Alcohol consumption \> approximately 20 g alcohol/day (2.5 units/day)
* BMI \<19.5 or \> 35
Minimum Eligible Age

45 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Danisco

INDUSTRY

Sponsor Role collaborator

Coressence LTD

UNKNOWN

Sponsor Role collaborator

Quadram Institute Bioscience

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Paul Kroon

Role: PRINCIPAL_INVESTIGATOR

Quadram Institute Bioscience

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Institute of Food Research

Norwich, Norfolk, United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Saha S, Hollands W, Needs PW, Ostertag LM, de Roos B, Duthie GG, Kroon PA. Human O-sulfated metabolites of (-)-epicatechin and methyl-(-)-epicatechin are poor substrates for commercial aryl-sulfatases: implications for studies concerned with quantifying epicatechin bioavailability. Pharmacol Res. 2012 Jun;65(6):592-602. doi: 10.1016/j.phrs.2012.02.005. Epub 2012 Feb 25.

Reference Type DERIVED
PMID: 22373658 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IFR06-2009

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.